MedTrace Logo

NOVOCART 3D Treatment Following Microfracture Failure

NCT03219307 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-03-21

No results posted yet for this study

Summary

This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.

Conditions

  • Articular Cartilage Defect

Interventions

COMBINATION_PRODUCT

NOVOCART 3D

Matrix associated autologous chondrocyte implant

Sponsors & Collaborators

  • Aesculap Biologics, LLC

    lead INDUSTRY

Principal Investigators

  • Robert Spiro, PhD · Octane Biotherapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-30
Primary Completion
2026-01-31
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03219307 on ClinicalTrials.gov